Saturday 17 October 2026
Export ATRC’s income statement to Excel — free account
AtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 12.8%, EPS grew 238.5%, free cash flow fell 2.79% and total debt fell 4.43%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
56.09
1.69
−2.92%
Follow ATRC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
129.18 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.39 | 2.50 | 3.53 | 3.26 | |
P/FCF ratio |
58.91 | 58.32 | 103.31 | 562.68 | |
P/Operating CF |
61.36 | (345.09) | 94.32 | 63.23 | |
P/B ratio |
2.64 | 2.80 | 3.84 | 3.54 | |
Price to Tangible BV |
5.71 | 6.53 | 9.03 | 8.82 | |
EV/Sales |
2.26 | 2.40 | 3.40 | 3.16 | |
EV/EBITDA |
37.60 | 72.75 | 157.03 | 0.00 | |
EV/Operating CF |
19.80 | 20.59 | 31.67 | 37.91 | |
EV/FCF |
55.62 | 56.05 | 99.30 | 544.89 | |
Quick Ratio |
3.02 | 2.97 | 2.87 | 2.71 | |
Current Ratio |
4.22 | 4.29 | 3.96 | 3.87 | |
Net Debt/EBITDA |
(6.42) | (12.60) | (12.19) | (13.49) | |
Debt/Assets |
10.50% | 11.15% | 11.22% | 11.60% | |
Debt/Equity |
0.14 | 0.15 | 0.15 | 0.15 | |
Asset Turnover |
0.89 | 0.89 | 0.85 | 0.83 | |
Operating CF/Net income |
2.48 | (37.00) | 11.40 | (100.06) | |
Capex/Depreciation |
(0.70) | (0.72) | (0.31) | (0.49) | |
Interest Coverage |
7.33 | 0.39 | 1.66 | 0.14 | |
Research and Development Expense of Revenue |
17.19% | 17.16% | 17.44% | 17.05% | |
Selling, General and Administrative Expense of Revenue |
53.75% | 59.86% | 55.76% | 58.27% | |
Intangible Assets out of Total Assets |
0.41 | 0.44 | 0.43 | 0.45 | |
Share Based Compensation of Revenue |
8.02% | 7.98% | 8.01% | 9.25% | |
Graham Net Nets |
0.14 | 0.12 | 0.08 | 0.08 | |
Graham Number |
7.19 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.77% | (0.33%) | (0.60%) | (1.72%) | |
Free Cash Flow Yield |
1.70% | 1.71% | 0.97% | 0.18% | |
Revenue per Share |
3.16 | 2.92 | 2.94 | 2.80 | |
Operating CF per Share |
0.46 | (0.08) | 0.42 | 0.56 | |
Capex per Share |
(0.08) | (0.08) | (0.03) | (0.05) | |
Free Cash Flow per Share |
0.38 | (0.16) | 0.39 | 0.50 | |
Cash per Share |
3.45 | 3.02 | 3.51 | 3.09 | |
Shareholders Equity per Share |
10.61 | 10.17 | 10.30 | 9.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.61 | 10.17 | 10.30 | 9.94 | |
Free Cash Flow |
18.43 | (7.85) | 18.43 | 24.11 | |
Working Capital |
263.62 | 240.50 | 241.00 | 223.27 | |
Capital Expenditures |
(3.77) | (3.85) | (1.60) | (2.60) | |
Net Current Asset Value |
185.32 | 161.40 | 160.27 | 142.18 | |
EV/EBIT |
99.74 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.01 | 0.02 | |
Price to Operating Income |
105.64 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
72.99 | 67.32 | 63.50 | 58.94 | |
Average Payables |
30.76 | 27.87 | 25.17 | 28.60 | |
Average Inventory |
80.13 | 78.03 | 76.91 | 77.75 | |
Average Assets |
642.75 | 617.81 | 631.75 | 625.26 | |
Average Common Equity |
490.46 | 473.16 | 476.45 | 470.76 |
Columns are period end dates